var data={"title":"Esterified estrogens: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Esterified estrogens: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6144?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=esterified-estrogens-patient-drug-information\" class=\"drug drug_patient\">see &quot;Esterified estrogens: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708757\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Endometrial cancer: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Estrogens increase the risk of endometrial cancer.  Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of &quot;natural&quot; estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disease: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogens with and without progestins should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone (2.5 mg), relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Breast cancer: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative (WHI) study reported increased risks of invasive breast cancer in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone (2.5 mg) relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dementia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative Memory Study (WHIMS) a substudy of WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk vs benefits: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520098\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Menest</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167701\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Estragyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167718\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Estrogen Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167704\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b> Oral: 1.25 to 2.5 mg 3 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Female hypoestrogenism due to hypogonadism:</b> Oral: 2.5 to 7.5 mg/day in divided doses for 20 days followed by a 10-day rest period. Administer cyclically (3 weeks on and 1 week off). If bleeding does not occur by the end of the 10-day period, repeat the same dosing schedule; the number of courses to produce bleeding is dependent upon the responsiveness of the endometrium. If bleeding occurs before the end of the 10-day period, begin an estrogen-progestin cyclic regimen of 2.5 to 7.5 mg/day in divided doses for 20 days; during the last 5 days of estrogen therapy, give an oral progestin. If bleeding occurs before regimen is concluded, discontinue therapy and resume on the fifth day of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Female hypoestrogenism due to castration and primary ovarian failure:</b> Oral: 1.25 mg/day, cyclically. Adjust dosage upward or downward, according to the severity of symptoms and patient response. For maintenance, adjust dosage to lowest level that will provide effective control.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasomotor symptoms associated with menopause:</b> Oral: 1.25 mg/day administered cyclically (3 weeks on and 1 week off). If patient has not menstruated within the last 2 months or more, cyclic administration is started arbitrary. If the patient is menstruating, cyclical administration is started on day 5 of the bleeding. For short-term use only and should be discontinued as soon as possible. Re-evaluate at 3- to 6-month intervals for tapering or discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vulvar and vaginal atrophy associated with menopause:</b> Oral: 0.3 to &ge;1.25 mg/day, depending on the tissue response of the individual patient. Administer cyclically. For short-term use only and should be discontinued as soon as possible. Re-evaluate at 3- to 6-month intervals for tapering or discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic (appropriately selected patients):</b> Males and postmenopausal females: Oral: 10 mg 3 times/day for at least 3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167705\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15837998\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15837999\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520099\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Menest: 0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167663\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9518183\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food at same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104490\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167680\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of moderate-to-severe vulvar and vaginal atrophy associated with menopause; hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure); advanced prostatic cancer (palliation), metastatic breast cancer (palliation) in men and postmenopausal women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167725\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection in older women. Low-dose intravaginal estrogen (vaginal creams or tablets) are <i>acceptable</i> for dyspareunia, lower urinary tract infections, and other vaginal symptoms. Of note, women with a history of breast cancer not responding to non-hormonal therapies are advised to discuss the risks/benefits of low dose vaginal estrogen (estradiol less than  25 mcg twice weekly) with their healthcare provider (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Estrogens (oral and topical patch products only), with or without progestins, are identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International Issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Estragyn: Brand name for estrone vaginal [Canada] and estrogens esterified oral [Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167670\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebrovascular accident, edema, hypertension, local thrombophlebitis, myocardial infarction, pulmonary embolism, retinal thrombosis, venous thromboembolism </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chorea, dementia (exacerbation), depression, dizziness, exacerbation of epilepsy, headache, irritability, migraine, mood disorder, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Chloasma, erythema multiforme, erythema nodosum, pruritus, loss of scalp hair, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Change in libido, exacerbation of porphyria, fibrocystic breast changes, galactorrhea, hirsutism, hypocalcemia, menstrual disease (alterations in frequency and flow of menstrual patterns), premenstrual-like syndrome, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, bloating, carbohydrate intolerance, gallbladder disease, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Breakthrough bleeding, breast hypertrophy, breast tenderness, change in cervical ectropion, change in cervical secretions, cystitis-like syndrome, dysmenorrhea, endometrial hyperplasia, nipple discharge, vulvovaginal candidiasis, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Endometrial carcinoma, hemorrhagic eruption, malignant neoplasm of breast, malignant neoplasm of ovary, uterine fibroids (increased size)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, exacerbation of hepatic hemangioma (enlargement)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, leg cramps </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Contact lens intolerance, change in corneal curvature (steepening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Exacerbation of asthma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167683\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to estrogens or any component of the formulation; undiagnosed abnormal genital bleeding; DVT or PE (current or history of); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; known or suspected estrogen-dependent tumor; hepatic dysfunction or disease; known or suspected pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167667\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: <b>[US Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).</b> This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometrial cancer: <b>[US Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.</b> Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use caution in patients with asthma; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: <b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.</b> Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Adverse cardiovascular events have also been reported in males taking estrogens for prostate cancer. Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Migraine: Use caution with migraine; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; SLE: Use with caution in patients with SLE; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risks vs benefits: <b>[US Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.</b> Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. <b>Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167714\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2B6 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167672\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9425&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: May enhance the thrombogenic effect of Estrogen Derivatives. Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Estrogen Derivatives may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167695\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Folic acid absorption may be decreased. Routine use of ethanol increases estrogen level and risk of breast cancer; may also increase the risk of osteoporosis. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167687\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. This product is contraindicated for use during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167688\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Estrogen has been shown to decrease the quantity and quality of human milk; use only if clearly needed; monitor the growth of the infant closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167689\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with food at same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167677\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Menopausal symptoms; vulvar and vaginal atrophy: Assess need for therapy at 3- to 6-month intervals </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167666\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not &lt;90%. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. In males and following menopause in females, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167682\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed; high concentrations in the sex hormone target organs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Bound to sex hormone-binding globulin and albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as estradiol, estrone, estriol, and their glucuronide and sulfate conjugates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167686\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Menest Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $210.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.625 mg (100): $299.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg (100): $417.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Chlebowski RT, Aragaki AK, et al, &quot;Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,&quot; <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/22401913/pubmed\" target=\"_blank\" id=\"22401913\">22401913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Limacher M, Assaf AR, et al, &quot;Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.&quot; <i>JAMA</i>, 2004, 291(14):1701-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/15082697/pubmed\" target=\"_blank\" id=\"15082697\">15082697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chlebowski RT, Kuller LH, Prentice RL, et al, &quot;Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,&quot; <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/19196674/pubmed\" target=\"_blank\" id=\"19196674\">19196674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeSancho MT, Dorff T, and Rand JH, &quot;Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,&quot; <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/20581664/pubmed\" target=\"_blank\" id=\"20581664\">20581664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grodstein F, Stampfer MJ, Colditz GA, et al, &ldquo;Postmenopausal Hormone Therapy and Mortality,&rdquo; <i>N Engl J Med</i>, 1997, 336(25):1769-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/9187066/pubmed\" target=\"_blank\" id=\"9187066\">9187066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsia J, Langer RD, Manson JE, et al, &quot;Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,&quot; <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/16476878/pubmed\" target=\"_blank\" id=\"16476878\">16476878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo; <i>JAMA</i>, 1998, 280(7):605-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/9718051/pubmed\" target=\"_blank\" id=\"9718051\">9718051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menest (estrogens, esterified) [prescribing information]. Bristol, TN: Monarch Pharmaceuticals, Inc; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo; <i>JAMA</i>, 2009, 302(3):298-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/19602689/pubmed\" target=\"_blank\" id=\"19602689\">19602689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society [NAMS], &quot;The 2012 Hormone Therapy Position Statement of The North American Menopause Society,&quot; <i>Menopause</i>, 2012, 19(3):257-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/22367731/pubmed\" target=\"_blank\" id=\"22367731\">22367731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;<i>JAMA</i>, 2002, 288(3):321-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/12117397/pubmed\" target=\"_blank\" id=\"12117397\">12117397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 289(20):2651-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/12771112/pubmed\" target=\"_blank\" id=\"12771112\">12771112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at <a href=\"http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Vlijmen EF, Veeger NJ, Middeldorp S, et al, &quot;Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,&quot; <i>Blood</i>, 2011, 118(8):2055-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/21659542/pubmed\" target=\"_blank\" id=\"21659542\">21659542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winship KA, &ldquo;Unopposed Oestrogens,&rdquo; <i>Adverse Drug React Acute Poisoning Rev</i>, 1987, 6(1):37-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esterified-estrogens-drug-information/abstract-text/3303864/pubmed\" target=\"_blank\" id=\"3303864\">3303864</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9425 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708757\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520098\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F167701\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F167718\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F167704\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F167705\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15837998\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15837999\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520099\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F167663\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9518183\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104490\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F167680\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F167725\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F167670\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F167683\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F167667\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F167714\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F167672\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F167695\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F167687\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F167688\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F167689\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F167677\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F167666\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F167682\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F167686\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9425|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=esterified-estrogens-patient-drug-information\" class=\"drug drug_patient\">Esterified estrogens: Patient drug information</a></li></ul></div></div>","javascript":null}